Li-Tzong Chen

Li-Tzong Chen, Chair Professor

Chair, Center for Cancer Research
Organization: Kaohsiung Medical University
Nationality: Taiwan
Email: Leochenk153@gmail.com
Curriculum Vitae

Brief Introduction

Dr. Chen is GI Oncologist who has devoted to developing effective, tolerable and affordable chemotherapy for the management of pancreatobiliary cancer through investigator-initiated trials.

Specialty

Education

Experience

Selected Publications

  1. Yeh CM, Yu CC, Lee AF, Cheng SM, Hsu CW, Chiang NJ, Hou YC, Tsai HJ, Chen SH, Yen CJ, Wang CJ, Chao YJ, Chuang SC, Du JS, Hwang DY#, Shan YS#, Chen LT#, Su YY*. A New CA19-9 cut-off value identifies Lewis antigen status and refines prognostic stratification in PDAC. Clin Cancer Res 2026 Jul 1;32(13):2722-2731.
  2. Chiang NJ#, Su YY#, Ho IW, Bai LY, Li CP, Chen JS, Hsiao CF, Tsou HH, Hsu C, Chiu TJ, Hsieh YY, Rau KM, Ho CL, Shan YS*, Chen LT*. SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TCOG T5217). Eur J Cancer. 2026 Feb 25;235:116229.
  3. Su YY, Bai LY, Huang CJ, Chiu CF, Wang HT, Du JS, Wang HC, Chuang SC, Shih YH, Lin HC, Shan YS, Chen LT*. TCOG T5221 trial: A phase II randomized study of gemcitabine and nab-paclitaxel in combination with S- 1/LV (GASL) or oxaliplatin (GAP) as first-line treatment for metastatic pancreatic cancer. Ann Oncol 2024;35 (S2): pp. S932-933
  4. Tsai HJ, Yang SH, Hsiao CF, Kao HF, Su YY, Shan YS, Yen CJ, Du JS, Hsu C, Wu IC, Chen LT*. A phase 1 study of biweekly nab-paclitaxel/oxaliplatin/S-1/LV for advanced upper gastrointestinal cancers: TCOG T1216 study. Oncologist. 2024 Oct 3;29(10):e1396-e1405.
  5. Su YY#, Chao YJ#, Wang CJ#, Liao TK, Su PJ, Huang CJ, Chiang NJ, Yu YT, Tsai HM, Chen LT*, Shan YS*. The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer: a cross sectional study. Int J Surg. 2023 Sep; 109(9): 2614–23.
  6. Su YY#, Chiang NJ#, Chang JS, Wang YW, Li YJ, Yu CC, Hwang DY, Shan YS, Chen LT*.The association between UGT1A1 polymorphisms and treatment toxicities of liposomal irinotecan (PEP02, nal-IRI). ESMO Open 2023;8(1):100746.
  7. Bai LY, Li CP, Shan YS, Chunag SC, Chen JS, Chiang NJ, Chen YY, Tsou HH, Chuang MH, Chiu CF, Chen LT*. A prospective phase II study of biweekly S-1, leucovorin, and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma –TCOG T1217 study. Eur J Cancer 2022 Sep;173:123-132
  8. Su YY#, Ting YL#, Wang CJ, Chao YJ, Liao TK, Su PJ, Chiang NJ , Liao IC, Yu YT, Liu YS, Tsai HM, Li YJ, Huang CJ, Liu IT, Tsai HJ, Yen CJ, Shan YS*, Chen LT*. Improved survival with induction chemotherapy and conversion surgery in locally advanced unresectable pancreatic cancer: a single institution experience. Am J Cancer Res 2022 May;12(5):2189-202
  9. Su YY, Chiu YF, Li CP, Yang SH, Lin J, Lin SJ, Chang PY, Chiang NJ, Shan YS, Ch'ang HJ, Chen LT*. A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the TCOG T2212 study. Br J Cancer. 2022 Apr;126(7):1018-26.
  10. Chiang NJ, Tsai KK, Hsiao CF, Yang SH, Hsiao HH, Shen WC, Hsu C, Lin YL, Chen JS*, Shan YS*, Chen LT*. A multicentre, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma -TCOG T1211 study. Eur J Cancer. 2020 Jan; 124: 123-130.
  11. Bang YJ, Li CP, Lee KH, Chiu CF, Park JO, Shan YS, Kim JS, Chen JS, Shim HJ, Rau KM, Choi HJ, Oh DY, Belanger B, Chen LT*. Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: subgroup analysis of the NAPOLI-1 study. Cancer Sci 2020 Feb;111(2):513-527.
  12. Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartsmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen LT* for the NAPOLI-1 Study Group. Nanoliposomal irinotecan with 5-fluorouracil and leucovorin in metastatic pancreatic cancer after prior gemcitabine-based therapy (NAPOLI-1): a global, randomized, open-label phase 3 trial. Lancet 2016 Feb;387(10018):545-57.
  13. Chang TC, Shiah HS, Yang CH, Cheng AL, Yeh CG, Chang JY*, Chen LT*. Phase I study of liposome encapsulated irinotecan (PEP02) in advanced solid tumor patients. Cancer Chemother Pharmacol. 2015 Mar;75(3):579-86
  14. Ko AH, Tempero MA, Shan YS, Su WC, Lin YL, Dito E, Ong A, Wang YW, Yeh G, Chen LT*. A multinational phase 2 study of nanoliposomal irinotecan (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. Br J Cancer 2013 Aug 20;109:920-5
  15. Ch’ang HJ, Lin YL, Wang HP, Chang MC, Hsu CH, Tien YW, Chen JS, Hsieh RK, Lin PW, Shan YS, Cheng AL, Chang JY, Hwang TL, Chen LT* Induction chemotherapy with gemcitabine, oxaliplatin and 5-FU/leucovorin followed by concomitant chemoradiation in patients with locally advanced pancreatic cancer: a Taiwan Cooperative Oncology Group (T1204) phase II study. Int J Rad Oncol Biol Physics 2011;81:e749-57.
  16. Ch’ang HJ, Huang CL, Wang HP, Hsiah HS, Chang MC, Jan CM, Chen JS, Tien YW, Hwang TL, Lin JT, Cheng AL, Chen LT*. Phase II study of biweekly gemcitabine followed by oxaliplatin & simplified 48-hr infusion 5-FU/leucovorin (GOFL) in advanced pancreatic cancer. Cancer Chemother Pharmacol. 2009;64:1173-9
  17. Shiah HS, Cheng AL, Hsu C, Hsu CH, Liu TW, Chang JY, Jan CM, Chao Y, Yu WL, Chung TR, Whang-Peng J, Chen LT*. Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer. J Gastroenterol Hepatol 2006; 21:531-6